| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8785816 | Cancer Treatment Reviews | 2018 | 36 Pages |
Abstract
Based on ESMO-MCBS scores, dose-dense paclitaxel and intraperitoneal chemotherapy cannot be recommended as standard treatment. Bevacizumab should be considered only in the high-risk population. The ESMO-MCBSv1.1. helps to summarise reported studies on controversial treatment regimens, and identifies their weaknesses.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
K.E. Broekman, M. Jalving, H. van Tinteren, C. Sessa, A.K.L. Reyners,